News
SGHT
4.910
+1.24%
0.060
Discover 3 Promising Penny Stocks With Market Caps Over $20M
Simply Wall St · 1d ago
Weekly Report: what happened at SGHT last week (0601-0605)?
Weekly Report · 2d ago
Sight Sciences Shareholders Reelect Directors, Ratify Auditor
TipRanks · 4d ago
Weekly Report: what happened at SGHT last week (0525-0529)?
Weekly Report · 06/01 10:39
Sight Sciences Price Target Raised to $5.15/Share From $4.35 by Citigroup
Dow Jones · 05/28 20:18
Sight Sciences Is Maintained at Neutral by Citigroup
Dow Jones · 05/28 20:18
Citigroup Maintains Neutral on Sight Sciences, Raises Price Target to $5.15
Benzinga · 05/28 20:07
Sight Sciences price target raised to $5.15 from $4.35 at Citi
TipRanks · 05/28 12:14
Analysts Offer Insights on Healthcare Companies: Sight Sciences (SGHT) and Universal Health (UHS)
TipRanks · 05/27 10:30
Weekly Report: what happened at SGHT last week (0518-0522)?
Weekly Report · 05/25 10:43
Top Executive Makes Notable Move With Sight Sciences Stock
TipRanks · 05/20 02:11
Weekly Report: what happened at SGHT last week (0511-0515)?
Weekly Report · 05/18 10:43
Weekly Report: what happened at SGHT last week (0504-0508)?
Weekly Report · 05/11 10:40
Sight Sciences (SGHT) Q1 Loss Of US$0.24 EPS Tests Margin Improvement Narrative
Simply Wall St · 05/08 09:41
Sight Sciences Earnings Call Signals Disciplined Growth
TipRanks · 05/08 02:38
Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF), Sight Sciences (SGHT) and Gyre Therapeutics (GYRE)
TipRanks · 05/07 13:01
Analysts Have Conflicting Sentiments on These Healthcare Companies: RxSight (RXST), Sight Sciences (SGHT) and Sarepta Therapeutics (SRPT)
TipRanks · 05/07 12:32
Stifel Nicolaus Sticks to Their Buy Rating for Sight Sciences (SGHT)
TipRanks · 05/07 11:44
Piper Sandler Reaffirms Their Buy Rating on Sight Sciences (SGHT)
TipRanks · 05/07 11:32
Sight Sciences signals $83M-$89M 2026 revenue outlook while targeting $6M-$8M dry eye sales
Seeking Alpha · 05/07 09:02
More
Webull provides a variety of real-time SGHT stock news. You can receive the latest news about Sight Sciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SGHT
Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.